J Xu1, H Chen, T Ma, X Wu. 1. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China. jpxu@tjh.tjmu.edu.cn
Abstract
OBJECTIVE: To analyze the safety and possibility of terminating early pregnancy up to 49 days gestation after cesarean section with mifepristone and misoprostol. METHODS: One-hundred and ninety-two early pregnant women were recruited, of which, 35 cases with uterine cicatrix and 157 cases were no-uterine cicatrix as control group. All of them took 25 mg of mifepristone, b.i.d. for 3 days and 600 microg of misoprostol on the 4th day. RESULTS: Of the 35 cases with uterine cicatrix, 33 achieved complete abortion after medical abortion. The complete abortion rate was 94.29% (95% CI 81-99%) in the cicatrix group and 89.81% (95% CI 75-91%) in the control group. There were no obvious complications detected in the cicatrix group. CONCLUSION: For the termination of early pregnancy in scarred uterus, administration of mifepristone and misoprostol is safe and effective, and a further large series study needs be done to confirm its acceptability as a routine medication in such situations.
OBJECTIVE: To analyze the safety and possibility of terminating early pregnancy up to 49 days gestation after cesarean section with mifepristone and misoprostol. METHODS: One-hundred and ninety-two early pregnant women were recruited, of which, 35 cases with uterine cicatrix and 157 cases were no-uterine cicatrix as control group. All of them took 25 mg of mifepristone, b.i.d. for 3 days and 600 microg of misoprostol on the 4th day. RESULTS: Of the 35 cases with uterine cicatrix, 33 achieved complete abortion after medical abortion. The complete abortion rate was 94.29% (95% CI 81-99%) in the cicatrix group and 89.81% (95% CI 75-91%) in the control group. There were no obvious complications detected in the cicatrix group. CONCLUSION: For the termination of early pregnancy in scarred uterus, administration of mifepristone and misoprostol is safe and effective, and a further large series study needs be done to confirm its acceptability as a routine medication in such situations.
Authors: Beatrice A Chen; Matthew F Reeves; Mitchell D Creinin; Jerry M Gilles; Kurt Barnhart; Carolyn Westhoff; Jun Zhang Journal: Am J Obstet Gynecol Date: 2008-02-15 Impact factor: 8.661